Current Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.

Minerva Cardiology and Angiology, published by EDIZIONI MINERVA MEDICA, is a prominent journal in the field of cardiology and cardiovascular medicine, with an ISSN of 2724-5683 and E-ISSN of 2724-5772. Established in 2021, this journal aims to foster the dissemination of cutting-edge research, clinical practice guidelines, and innovative methodologies relevant to cardiovascular health. As of 2023, it holds a commendable Q3 quartile rank in its category, reflecting its growing influence within the scientific community. The journal is indexed in Scopus, where it ranks #221 out of 387 in its field, placing it in the 43rd percentile overall. Although it currently does not offer Open Access options, articles published in Minerva Cardiology and Angiology contribute significantly to ongoing discussions and advancements in heart and vascular health. The journal serves as an invaluable resource for researchers, healthcare professionals, and students seeking to stay informed on the latest developments in cardiology.

JAMA Psychiatry, published by the American Medical Association, stands as a leading peer-reviewed journal in the fields of psychiatry and mental health, featuring an impressive impact factor that reflects its significance in advancing research and clinical practice. With an ISSN of 2168-622X and an E-ISSN of 2168-6238, this journal operates on a comprehensive access model that allows for the dissemination of vital research findings to a global audience. Since its inception in 2013, JAMA Psychiatry has consistently ranked in the top quartile (Q1) in both the Medicine (miscellaneous) and Psychiatry and Mental Health categories, with a remarkable Scopus rank of #4 out of 567, placing it in the 99th percentile. Addressed from its headquarters in Chicago, Illinois, the journal's objectives encompass the publication of original clinical research, innovative treatment strategies, and insightful reviews that enrich the understanding of psychiatric disorders. By bridging the gap between research and real-world application, JAMA Psychiatry remains an essential resource for researchers, clinicians, and students dedicated to improving mental health outcomes.

CURRENT HYPERTENSION REPORTS is a premier journal dedicated to advancing the field of cardiovascular health, particularly focusing on hypertension and its multifaceted implications. Published by SPRINGER, this influential journal boasts an impressive impact factor and ranks in the top Q1 category among Internal Medicine journals, placing it within the elite 88th percentile of its field according to Scopus rankings. Since its inception in 1999, it has provided a platform for cutting-edge research and clinical insights, facilitating knowledge exchange among researchers, healthcare professionals, and students alike. With a commitment to publishing high-quality articles without open access barriers, CURRENT HYPERTENSION REPORTS remains an essential resource for those looking to stay abreast of the latest developments and trends in hypertension management and treatment.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

The Anatolian Journal of Cardiology, published by KARE PUBL, stands as a vital resource in the field of Cardiology and Cardiovascular Medicine. With an ISSN of 2149-2263 and E-ISSN 2149-2271, this Open Access journal has been fostering the dissemination of critical research since 2001, ensuring that high-quality content is freely available to a global audience. Based in Turkey, the journal aims to bridge gaps in cardiological knowledge through rigorous peer-reviewed articles that span a wide range of topics, from innovative clinical practices to groundbreaking research findings. While its current ranking places it in the Q3 category of cardiology journals, the Anatolian Journal of Cardiology continues to strive towards enhancing its impact, currently holding a Scopus rank of 236 out of 387. Researchers, practitioners, and students alike will find this journal an essential platform for keeping abreast of the latest developments in cardiovascular health.

The International Journal of Hypertension, published by HINDAWI LTD, is a pivotal open-access journal dedicated to advancing knowledge in the field of hypertension and cardiovascular health. Since its inception in 2010, the journal has provided a vital platform for researchers, clinicians, and students to disseminate innovative findings and comprehensive reviews spanning various aspects of hypertension management, pathophysiology, and epidemiology. Residing in Q3 of the Internal Medicine category and ranked 75 out of 167 in the Scopus rankings, it reflects a commitment to quality and relevance in medical research. With a global reach, the journal aims to foster collaboration and knowledge exchange, contributing significantly to the scientific community's efforts to combat hypertension-related health issues. Accessible since 2010, this journal exemplifies the principles of open science, ensuring that critical research is available to all stakeholders in the field.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Turkish Journal of Nephrology, published by AVES, serves as a pivotal platform for disseminating significant research in the domains of nephrology, transplantation, and surgery. Since its establishment as an Open Access journal in 2019, it has gained traction for delivering high-quality, peer-reviewed articles that reflect the latest advancements and practices in these critical medical fields. Based in Turkey, this journal has rapidly become an important resource, particularly for researchers and healthcare professionals striving to enhance kidney healthcare strategies. Despite being categorized in the fourth quartile across its main categories for 2023 and having modest rankings within Scopus, its commitment to openness and accessibility fosters a collaborative academic environment that promotes knowledge sharing. We encourage scholars, practitioners, and students to engage with the journal's content to further drive innovation and improve patient outcomes in nephrology and associated disciplines.

Clinical Hypertension is a premier journal dedicated to advancing the field of hypertension and cardiovascular health, published by SpringerNature. Since its transition to an Open Access model in 2014, the journal has opened doors for researchers globally to share their findings without barriers, aiming to foster collaboration and innovation in this vital area of medicine. With a current impact factor that positions it in the Q2 quartile for both Cardiology and Cardiovascular Medicine and Internal Medicine, Clinical Hypertension is recognized for its scholarly contributions, reflected in its Scopus rankings (Rank #100/387 in Cardiology and Rank #52/167 in Internal Medicine), which place it in the top percentiles of these competitive fields. Covering a diverse range of topics within hypertension research, it serves as an essential resource for clinicians, researchers, and students alike, promising to keep its audience informed of the latest developments and breakthroughs from its inception in 2017 through to 2024.